title: Effect of dopamine infusion on thyroid hormone tests and prolactin levels in very low birth weight infants.
abstract: OBJECTIVE
  To evaluate the effect of dopamine on thyroid hormone tests and prolactin (PRL) and to assess requirement for L-thyroxin (LT4).
  
  
  METHODS
  The infants (n = 102) were divided into three groups (Group 1; received no dopamine, Group 2 received ≤25 mg/kg cumulative dose and Group 3; received >25 mg/kg cumulative dose). Blood samples were taken at 6-8 days (timepoint 1), 13-15 days (timepoint 2), and 4-6 weeks of life (timepoint 3).
  
  
  RESULTS
  Respiratory distress syndrome was higher in group 2 and 3. Patnet ductus arteriosus was higher in group 3 than in groups 1 and 2. Duration and cumulative dose in group 3 were higher than group 2. There was no difference between thyroid hormones that were taken after stopping infusion at timepoint 3 among all groups. No therapy with LT4 was needed. PRL levels were higher at timepoint 1 in group 1 than compared to group 2 and 3 (p < 0.05), and no difference between group 2 and 3 (p > 0.05). This difference was disappeared at following timepoints.
  
  
  CONCLUSIONS
  The release of TSH, FT3, FT4 and PRL were not inhibited and prophylactic thyroid hormone treatment was not required in VLBW infants receiving dopamine infusions.
authors.affiliation: Zekai Tahir Burak Maternity Teaching Hospital , Ankara , Turkey and.
authors.forename: Sadrettin
authors.initials: S
authors.lastname: Ekmen
authors.forename: Halil
authors.initials: H
authors.lastname: Degirmencioglu
authors.forename: Nurdan
authors.initials: N
authors.lastname: Uras
authors.forename: Mehmet Yekta
authors.initials: MY
authors.lastname: Oncel
authors.forename: Fatma Nur
authors.initials: FN
authors.lastname: Sari
authors.forename: Fuat Emre
authors.initials: FE
authors.lastname: Canpolat
authors.forename: Suna Serife
authors.initials: SS
authors.lastname: Oguz
authors.forename: Ugur
authors.initials: U
authors.lastname: Dilmen
mesh_terms: D015415:Biomarkers / Q000097:blood; D004298:Dopamine / Q000008:administration & dosage / Q000009:adverse effects*; D005260:Female; D006801:Humans; D007037:Hypothyroidism / Q000097:blood / Q000139:chemically induced* / Q000175:diagnosis / Q000188:drug therapy; D007231:Infant, Newborn; D007234:Infant, Premature; D007235:Infant, Premature, Diseases / Q000097:blood / Q000139:chemically induced* / Q000175:diagnosis / Q000188:drug therapy; D019102:Infant, Very Low Birth Weight; D007262:Infusions, Intravenous; D008297:Male; D011388:Prolactin / Q000097:blood*; D013566:Sympathomimetics / Q000008:administration & dosage / Q000009:adverse effects*; D013960:Thyroid Function Tests; D013963:Thyroid Hormones / Q000097:blood*; D013974:Thyroxine / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D015415:Biomarkers; D013566:Sympathomimetics; D013963:Thyroid Hormones; D011388:Prolactin; D013974:Thyroxine; D004298:Dopamine
keywords: Dopamine; preterm; prolactin; thyroid hormone